In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Bioplastic straws an unlikely savior for coral
In Florida, researchers have developed a novel solution to keeping young, vulnerable coral from being eaten by predatory fish: protective cages made from bioplastic...
Canadian rapper Drake photographed sporting biobased EVA slip ons from Kane
In Canada, “Hotline Bling” rapper Drake has been seen sporting pink biobased slip-on shoes designed by Kane.
Founded in 2020 by former Maverik Lacrosse CEO...
Sorry parents, fruit waste glitter is still a pain to clean up
In the United Kingdom, scientists at Cambridge University have developed biodegradable glitter made from nanocrystals of cellulose extracted from fruit waste.
The sustainable sparkle solution...